These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 2108854)
1. A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease. Levine MN; Weitz J; Turpie AG; Andrew M; Cruickshank M; Hirsh J Chest; 1990 Apr; 97(4 Suppl):168S-171S. PubMed ID: 2108854 [TBL] [Abstract][Full Text] [Related]
2. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Levine M; Hirsh J; Weitz J; Cruickshank M; Neemeh J; Turpie AG; Gent M Chest; 1990 Dec; 98(6):1473-9. PubMed ID: 2123152 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism. Diehl JL; Meyer G; Igual J; Collignon MA; Giselbrecht M; Even P; Sors H Am J Cardiol; 1992 Dec; 70(18):1477-80. PubMed ID: 1442621 [TBL] [Abstract][Full Text] [Related]
4. Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group. Agnelli G; Iorio A; Parise P; Goldhaber SZ; Levine MN Blood Coagul Fibrinolysis; 1997 Jun; 8(4):216-22. PubMed ID: 9199818 [TBL] [Abstract][Full Text] [Related]
6. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. Goldhaber SZ; Agnelli G; Levine MN Chest; 1994 Sep; 106(3):718-24. PubMed ID: 8082347 [TBL] [Abstract][Full Text] [Related]
7. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. Goldhaber SZ; Kessler CM; Heit JA; Elliott CG; Friedenberg WR; Heiselman DE; Wilson DB; Parker JA; Bennett D; Feldstein ML J Am Coll Cardiol; 1992 Jul; 20(1):24-30. PubMed ID: 1607532 [TBL] [Abstract][Full Text] [Related]
8. Bolus, front-loaded, and accelerated thrombolytic infusions for myocardial infarction and pulmonary embolism. Levine MN Chest; 1991 Apr; 99(4 Suppl):128S-134S. PubMed ID: 2009809 [TBL] [Abstract][Full Text] [Related]
9. [rt-PA in extracardiac thromboembolic vascular occlusions]. Cortellaro M; Cofrancesco E; Polli EE Ann Ital Med Int; 1990; 5(1):61-9. PubMed ID: 2119673 [TBL] [Abstract][Full Text] [Related]
10. Thrombolysis in venous thromboembolism. An international perspective. Goldhaber SZ Chest; 1990 Apr; 97(4 Suppl):176S-181S. PubMed ID: 2108856 [TBL] [Abstract][Full Text] [Related]
11. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138 [TBL] [Abstract][Full Text] [Related]
12. Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: a systematic review and meta-analysis. Zhang Z; Zhai ZG; Liang LR; Liu FF; Yang YH; Wang C Thromb Res; 2014 Mar; 133(3):357-63. PubMed ID: 24412030 [TBL] [Abstract][Full Text] [Related]
13. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Jang IK; Gold HK; Leinbach RC; Fallon JT; Collen D Circ Res; 1990 Dec; 67(6):1552-61. PubMed ID: 2123135 [TBL] [Abstract][Full Text] [Related]
14. New developments in thrombolytic therapy. Collen D; Gold HK Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372 [TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic therapy of deep vein thrombosis with continuous intravenous infusion of a recombinant tissue plasminogen activator. Zimmerman R; Gürsoy A; Horn A; Harenberg J; Diehm C; Kübler W Semin Thromb Hemost; 1991 Jan; 17(1):48-54. PubMed ID: 1904629 [TBL] [Abstract][Full Text] [Related]
16. Coagulation alterations due to local fibrinolytic therapy with recombinant tissue-type plasminogen activator (rt-PA) in patients with peripheral arterial occlusive disease. Rauber K; Heidinger KS; Kemkes-Matthes B Cardiovasc Intervent Radiol; 1997; 20(3):169-73. PubMed ID: 9134838 [TBL] [Abstract][Full Text] [Related]
17. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384 [TBL] [Abstract][Full Text] [Related]
18. [Repeated local thrombolysis in a patient with axillary and subclavian vein injury and thrombosis]. Sárník S; Hofírek I Vnitr Lek; 2009 Nov; 55(11):1102-4. PubMed ID: 20017444 [TBL] [Abstract][Full Text] [Related]
19. Recombinant tissue-type plasminogen activator in canine embolic pulmonary hypertension. Effects of bolus versus short-term administration on dynamics of thrombolysis and on pulmonary vascular pressure-flow characteristics. Prewitt RM; Shiffman F; Greenberg D; Cook R; Ducas J Circulation; 1989 Apr; 79(4):929-38. PubMed ID: 2494007 [TBL] [Abstract][Full Text] [Related]
20. [Successful lysis of a septic thrombosis of the superior vena cava using recombinant tissue-plasminogen activator]. Schranz D; Haugwitz D; Zimmer B; Schumacher R Klin Padiatr; 1991; 203(5):363-5. PubMed ID: 1942943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]